Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4843507 | 1.00 | ALDH1A1 (0.44) | ALDH1A1MAPTNPSR1HTTTDP1 | |
| SCHEMBL5791105 | 1.00 | ALDH1A1 (0.44) | ALDH1A1MAPTNPSR1HTTTDP1 | |
| SCHEMBL4834022 | 0.82 | GRM2 (0.33) | — | |
| SCHEMBL4834368 | 0.82 | GRM2 (0.33) | — | |
| SCHEMBL5792149 | 0.81 | MEN1 (0.36) | ALDH1A1MAPTTDP1KMT2ATHRB | |
| SCHEMBL4845496 | 0.81 | MEN1 (0.36) | ALDH1A1MAPTTDP1KMT2ATHRB | |
| SCHEMBL4841082 | 0.79 | ALDH1A1 (0.38) | ALDH1A1MAPTNPSR1KMT2ATSHR | |
| SCHEMBL4841551 | 0.79 | ALDH1A1 (0.38) | ALDH1A1MAPTNPSR1KMT2ATSHR | |
| SCHEMBL5795559 | 0.79 | ALDH1A1 (0.38) | ALDH1A1MAPTNPSR1KMT2ATSHR | |
| SCHEMBL8313398 | 0.78 | ALDH1A1 (0.42) | ALDH1A1MAPTNPSR1HTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342007-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| US-7342007-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| US-7342007-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| US-20060183732-A1 | Novel lactams and uses thereof | ASTRAZENECA AB (SE) | 2006-08-17 | — | — | US | disclosed |
| WO-2004080983-A1 | NOVEL LACTAMS AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183732-A1 | Novel lactams and uses thereof | BACE1, BACE2, APP | ALDH1A1 2419/4885MAPT 45/4885NPSR1 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.